clinical trial · NCT02228681
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation·phase2·completed·n = 74
Advanced, Persistent, or Recurrent Endometrial CancerEverolimusTamoxifenLetrozoleMedroxyprogesterone Acetate
brief summary
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.
started
May 21, 2015
primary completion
Jan 1, 2018
completion
Aug 22, 2024
last updated
Sep 19, 2024
official title
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol